Alaunos Therapeutics, Inc. earnings releases TCRT

Annual Quarterly

Alaunos Therapeutics, Inc. last reported quarterly results on Oct 10, 2024, for Q3 FY2024 (the quarter ended Sep 30, 2024): revenue of $0 and diluted EPS of -$0.70. It usually reports 10–45 days after a quarter ends.

Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 10–45 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.

Released	Quarter	Revenue	Net income	Diluted EPS
Oct 10, 2024 10 days after quarter end	Q3 FY2024 ended Sep 30, 2024	0	-1 +86.7%	-0.70 +86.8%
Nov 14, 2023 45 days after quarter end	— ended Sep 30, 2023	—	—	—
Aug 14, 2023 45 days after quarter end	— ended Jun 30, 2023	—	—	—
May 10, 2023 40 days after quarter end	— ended Mar 31, 2023	—	—	—
Mar 7, 2023 66 days after quarter end	— ended Dec 31, 2022	—	—	—
Nov 14, 2022 45 days after quarter end	— ended Sep 30, 2022	—	—	—
Aug 15, 2022 46 days after quarter end	— ended Jun 30, 2022	—	—	—
May 16, 2022 46 days after quarter end	— ended Mar 31, 2022	—	—	—

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: TCRT (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Fort Lauderdale, FL
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1107421
Former names: ZIOPHARM ONCOLOGY INC (until Jan 4, 2022); EASYWEB INC (until Sep 19, 2005)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.